Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted TherapyZakaria Chakrani, Vaibhav G. Patel, George Mellgard et al.|American Journal of Clinical Oncology|2024Cited by 2
Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted TherapyGeorge Mellgard, Vaibhav G. Patel, Stephen McCroskery et al.|American Journal of Clinical Oncology|2024Cited by 2
Performance status and end-of-life outcomes in patients with metastatic castration resistant prostate cancer treated with androgen receptor targeted therapyGeorge Mellgard, Vaibhav G. Patel, William Oh et al.|Research Square|2023Cited by 1
The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)Zakaria Chakrani, Vaibhav G. Patel, George Mellgard et al.|Clinical Genitourinary Cancer|2024Cited by 1